Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC) | ||
By: PR Newswire Association LLC. - 18 Mar 2024 | Back to overview list |
|
INCHEON, Korea and WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. The latest investment reflects Samsung's commitment to discover and explore new opportunities in biopharmaceuticals to address unmet therapeutic needs. Samsung affiliates will work with BrickBio to evaluate, manufacture, and develop advanced molecules and therapies using BrickBio's proprietary protein engineering technology for antibody-drug conjugates (ADCs), AAV gene therapy, and other modalities. BrickBio's technology uses an expanded genetic code to incorporate synthetic amino acids into proteins, all completed within a living cell. These synthetic amino acids enable the creation of precision biologics, an exciting new class of therapeutics with broad application and potential. "We're pleased to receive this support from Samsung, as well as the recognition of the potential for our advanced protein engineering technology to provide novel solutions for challenging medical conditions," said John Boyce, the Chief Executive Officer and Co-Founder of BrickBio and Tiger Gene. "We look forward to using these proceeds to further our efforts in advancing our ADC candidates toward the clinic." "BrickBio's robust expanded genetic code in mammalian cells offer the potential to create molecules and therapies to address unmet needs," said Ho Sung Cho, the Executive Vice President and Head of Early Research and Development of Samsung Bioepis. BrickBio's innovation engine continues to expand the preclinical pipeline by discovering new and valuable programs that take full advantage of its technologies. These novel programs have the potential to address a wide range of diseases with new or improved mechanisms of action, providing the company with a rich set of programs to develop internally and/or in partnership with leading pharmaceutical companies. About BrickBio, Inc. For more information, please visit www.brickbio.com. Corporate Contact: About Samsung Ventures Media Contact – Samsung Bioepis Anna Nayun Kim, nayun86.kim@samsung.com View original content to download multimedia:https://www.prnewswire.com/news-releases/samsung-invests-in-brickbio-to-develop-advanced-molecules-and-therapies-using-protein-engineering-technology-for-antibody-drug-conjugates-adc-302091366.html SOURCE BrickBio |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |